+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07606066

Identification and Characterization of Patients With Type 2 Diabetes Mellitus for Participation in Current or Future Clinical Studies

Led by AstraZeneca · Updated on 2026-08-25

2150

Participants Needed

76

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are identifying and characterizing patients with Type 2 Diabetes Mellitus T2DM to support participation in current or future clinical studies focused on this condition. The study aims to observe trends in key medications used alongside diabetes treatments across various geographical areas, helping to better understand patient profiles and treatment patterns. Participants with T2DM who are inadequately managed by lifestyle changes alone or stable on glucose-lowering medications for at least 45 days will be observed. The study involves a single visit where assessments include collecting about 2 mL of blood and recording medical history, medication use, and HbA1c levels. This observational study does not administer treatments but gathers important health information. During the study visit, participants will provide demographic details, medical and surgical history, current medications, and blood samples to measure HbA1c levels. Researchers will also note referrals to ongoing or future T2DM studies. Participation requires signed consent and willingness to follow study procedures. The study concludes after the single visit, with no further follow-up required.

CONDITIONS

Brief Title

A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here